文献速递冠心病

稳定胸痛患者CT与有创冠脉造影后的健康状况结局:DISCHARGE随机临床试验预设二次分析

Health Status Outcomes After Computed Tomography or Invasive Coronary Angiography for Stable Chest Pain: A Prespecified Secondary Analysis of the DISCHARGE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

DISCHARGE试验预设二次分析纳入3561例稳定胸痛、冠心病中等概率患者,随机接受CT或有创冠脉造影,随访中位3.5年。两组生活质量与心绞痛结局无显著差异,女性基线及随访生活质量均差于男性,但改善幅度更大。

要点

  • CT与有创冠脉造影作为初始检查,3.5年生活质量和心绞痛结局无显著差异。
  • 女性患者基线及随访生活质量均差于男性,但生活质量改善幅度大于男性。
  • 有创冠脉造影组女性1年心绞痛发生率高于男性(10.2% vs 6.2%,P=.007)。

核心结论

  • 稳定胸痛中等风险患者中,CT与有创冠脉造影初始策略在3.5年生活质量和胸痛结局上无显著差异。
  • 女性患者基线和随访生活质量均差于男性,两种检查策略未改变此差异。

研究设计与样本

  • DISCHARGE随机临床试验预设二次分析,2015年10月至2019年4月在26个欧洲中心开展。
  • 纳入3561例稳定胸痛、冠心病中等概率患者,随机分配至CT或有创冠脉造影,随访中位3.5年。

主要发现

  • CT组1735例(96.0%)、有创冠脉造影组1671例(95.3%)完成至少1次健康状态评估。
  • 两组生活质量结局相似,所有生活质量指标均显著改善,例如EQ-5D-3L-VAS 3.5年减基线均值:CT=4.0(95%CI 3.1-4.9,P<.001),有创冠脉造影=4.6(95%CI 3.6-5.6,P=.002)。
  • HADS-D仅在CT组改善(均值-0.2,95%CI -0.4至0,P=.04),有创冠脉造影组未达显著(均值-0.2,95%CI -0.4至0,P=.12)。
  • 女性基线EQ-5D-3L-VAS较男性低5.2(95%CI 4.0-6.3,P<.001),3.5年时低3.1(95%CI 1.9-4.4,P<.001),但EQ-5D-3L-VAS改善更大(-1.9,95%CI -3.4至-0.5,P=.009)。
  • 3.5年时两组心绞痛结局相当,有创冠脉造影组女性1年心绞痛发生率高于男性(10.2% vs 6.2%,P=.007)。

临床怎么用

  • 稳定胸痛中等风险患者选择CT或有创冠脉造影作为初始检查时,可预期相似的生活质量和心绞痛结局。
  • 应关注女性患者生活质量基线更差且随访持续较差的特点,可能需要额外支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The effect of computed tomography (CT) vs invasive coronary angiography (ICA) on health status outcomes is unknown. OBJECTIVE: To evaluate CT and ICA first-test strategies on quality of life (QOL) and angina. DESIGN, SETTING, AND PARTICIPANTS: The Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE) randomized clinical trial, conducted between October 2015 and April 2019 in 26 European centers, followed up patients with stable chest pain and intermediate probability of coronary artery disease for a median 3.5 years. Data analysis was from December 2023 to July 2024. INTERVENTIONS: Random assignment to CT or ICA. MAIN OUTCOMES AND MEASURES: Patient-reported Euro QOL 5-dimensions descriptive system (EQ-5D-3L) visual analog scale (EQ-5D-3L-VAS) and 12-item Short Form Health Survey (SF-12) physical component score (SF-12-PCS) were primary prespecified QOL outcomes. Angina was the primary prespecified chest pain outcome. The EQ-5D-3L-VAS, summary index (EQ-5D-3L-SI), mental component summary (SF-12-MCS), and Hospital Anxiety and Depression Scale-anxiety subscale (HADS-A) and Hospital Anxiety and Depression Scale-anxiety subscale (HADS-D) were also evaluated. RESULTS: Among 3561 patients (mean [SD] age, 60.1 [10.1] years; 2002 female [56.2%]), 1735 (96.0%) in the CT group and 1671 (95.3%) in the ICA group completed at least 1 health status assessment during 3.5 years of follow-up. Health status outcomes were similar between groups, with significant improvements in all QOL outcomes (eg, mean EQ-5D-3L-VAS 3.5 year minus baseline score: CT = 4.0; 95% CI, 3.1-4.9; P < .001; ICA = 4.6; 95% CI, 3.6-5.6; P =.002), except HADS-D, which improved only in the CT group (mean EQ-5D-3L-VAS 3.5 year minus baseline score: CT = -0.2; 95% CI, -0.4 to 0; P = .04; ICA = -0.2; 95% CI, -0.4 to 0; P = .12). Female patients had worse baseline and follow-up QOL than male patients (eg, baseline EQ-5D-3L-VAS difference between men and women = 5.2; 95% CI, 4.0-6.3; P <.001 and at 3.5 years = 3.1; 95% CI, 1.9-4.4; P < .001) but showed greater improvements in EQ-5D-3L-VAS (-1.9; 95% CI, -3.4 to -0.5; P = .009), SF-12-PCS (-1.4; -2.1 to -0.7; P < .001), and HADS-A (0.3; 0-0.7; P = .04). Angina outcomes were comparable between groups at 3.5 years, with similar 1-year rates in the CT group but higher rates in female than male patients in the ICA group (10.2% vs 6.2%; P = .007). CONCLUSIONS AND RELEVANCE: Results of this secondary analysis of the DISCHARGE randomized clinical trial reveal that there was no significant difference in QOL or chest pain outcomes with CT vs ICA at 3.5 years. Female patients had worse health status than male patients at baseline and follow-up, and CT or ICA did not affect these differences. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02400229.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Rieckmann, Neumann, Maurovich-Horvat, et al. Health Status Outcomes After Computed Tomography or Invasive Coronary Angiography for Stable Chest Pain: A Prespecified Secondary Analysis of the DISCHARGE Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40366703. doi:10.1001/jamacardio.2025.0992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。